Article thumbnail

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies

By S. Mammoliti, V. Andretta, E. Bennicelli, F. Caprioni, D. Comandini, G. Fornarini, A. Guglielmi, A. Pessino, S. Sciallero, A. F. Sobrero, G. Mazzola, A. Lambiase and C. Bordignon


Background: asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose–response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and 45 μg/m2 as optimal biological and maximum-tolerated dose, respectively

Topics: Original Articles
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles